Clinical Trial Update: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of the insulin glargine/lixisenatide fixed-ratio combination (LixiLan) added to oral anti-diabetic drugs in adu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• insulin glargine/lixisenatide fixed-ratio combination (LixiLan)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED